Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients-Reference-Cited by-同舟云学术

Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients

Published:2021-03 Issue: Volume:104 Page:232-238
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Sharma Yogesh,Horwood Chris,Hakendorf Paul,Thompson Campbell

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference41 articles.

1. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality;Antes;Lancet Respir Med,2014

2. Early administration of oral Oseltamivir increases the benefits of influenza treatment;Aoki;J Antimicrob Chemother,2003

3. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples;Austin;Stat Med,2009

4. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies;Austin;Pharm Stat,2011

5. Australian influenza surveillance report no. 12 (reporting period 14 October to 27 October 2017;Australian Government Department of Health Canberra,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and prevention of influenza in geriatric patients;Expert Review of Clinical Pharmacology;2023-08-07

2. K‐medoids clustering of hospital admission characteristics to classify severity of influenza virus infection;Influenza and Other Respiratory Viruses;2023-03

3. Comparative effectiveness of oseltamivir versus peramivir for hospitalized children (aged 0-5 years) with influenza infection;International Journal of Infectious Diseases;2023-03

4. The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza;Contemporary Clinical Trials;2022-12

5. Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea;Epidemiology and Health;2022-03-12